Jasper Therapeutics, Inc.JSPREarnings & Financial Report
Nasdaq
JSPR Q4 2023 Key Financial Metrics
Revenue
$-118.0K
Gross Profit
N/A
Operating Profit
$-17.7M
Net Profit
$-16.6M
Gross Margin
N/A
Operating Margin
15021.2%
Net Margin
14051.7%
YoY Growth
70.5%
EPS
$-5.71
Jasper Therapeutics, Inc. Q4 2023 Financial Summary
Jasper Therapeutics, Inc. reported revenue of $-118.0K for Q4 2023, with a net profit of $-16.6M (14051.7% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $-118.0K |
|---|---|
| Net Profit | $-16.6M |
| Gross Margin | N/A |
| Operating Margin | 15021.2% |
| Report Period | Q4 2023 |
Jasper Therapeutics, Inc. Annual Revenue by Year
Jasper Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $-246.0K).
| Year | Annual Revenue |
|---|---|
| 2023 | $-246.0K |
| 2022 | $-115.0K |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $-72000 | $89000 | $268000 | $-400000 | $-70000 | $-109000 | $51000 | $-118000 |
| YoY Growth | -7300.0% | 2125.0% | 3077.8% | -426.3% | 2.8% | -222.5% | -81.0% | 70.5% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $80.5M | $70.4M | $59.1M | $48.4M | $138.8M | $124.2M | $110.4M | $94.9M |
| Liabilities | $12.4M | $11.6M | $11.5M | $12.4M | $13.6M | $14.0M | $16.3M | $16.5M |
| Equity | $68.1M | $58.8M | $47.6M | $36.0M | $125.2M | $110.2M | $94.1M | $78.4M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-14.2M | $-9.4M | $-9.6M | $-12.6M | $-10.3M | $-13.3M | $-12.0M | $-16.5M |